Immunotherapy in renal cell carcinoma: latest evidence and clinical implications
Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible fav...
Gespeichert in:
| Veröffentlicht in: | Drugs in Context 2018, Vol.7, p.212528-8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | |
| container_start_page | 212528 |
| container_title | Drugs in Context |
| container_volume | 7 |
| creator | Santoni, Matteo Massari, Francesco Di Nunno, Vincenzo Conti, Alessandro Cimadamore, Alessia Scarpelli, Marina Montironi, Rodolfo Cheng, Liang Battelli, Nicola Lopez-Beltran, Antonio |
| description | Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients. |
| doi_str_mv | 10.7573/dic.212528 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5992965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_78c641e04f204b16a89297c851445ad5</doaj_id><sourcerecordid>2055617610</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3598-8d7a4b68df2e39eb42de1f960b7c058c5ce8f0018b1c48b71669a35ec61b28403</originalsourceid><addsrcrecordid>eNpVkV1LHTEQhkNpqR_tjT-g7GUR1ibZfHohiLT2gNBe6HWYTWY1spucJnsE_717PCr1ZmaYeXlmmJeQI0ZPtNTdjxD9CWdccvOB7DMtaCs6az4-17Jl1rA9clDrPaVCUqU-kz1ujbVain3ydzVNm5TnOyywfmxiagomGBuP4xKg-JjyBKfNCDPWucGHGDB5bCCFxo8xRb-I47Qel2KOOdUv5NMAY8WvL_mQ3Pz6eX3xu736c7m6OL9qfSetaU3QIHplwsCxs9gLHpANVtFeeyqNlx7NQCkzPfPC9JopZaGT6BXruRG0OySrHTdkuHfrEicojy5DdM-NXG4dlDn6EZ02XgmGVAycip4pMJZb7Y1kQkgIcmGd7VjrTT9h8JjmAuM76PtJinfuNj84aReS2gK-vwBK_rdZHuWmWLcvhIR5Ux2nUiqmFdvefbyT-pJrLTi8rWHUbe10i51uZ-ci_vb_YW_SV_-6J3OWm4E</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2055617610</pqid></control><display><type>article</type><title>Immunotherapy in renal cell carcinoma: latest evidence and clinical implications</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Santoni, Matteo ; Massari, Francesco ; Di Nunno, Vincenzo ; Conti, Alessandro ; Cimadamore, Alessia ; Scarpelli, Marina ; Montironi, Rodolfo ; Cheng, Liang ; Battelli, Nicola ; Lopez-Beltran, Antonio</creator><creatorcontrib>Santoni, Matteo ; Massari, Francesco ; Di Nunno, Vincenzo ; Conti, Alessandro ; Cimadamore, Alessia ; Scarpelli, Marina ; Montironi, Rodolfo ; Cheng, Liang ; Battelli, Nicola ; Lopez-Beltran, Antonio</creatorcontrib><description>Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.</description><identifier>ISSN: 1745-1981</identifier><identifier>ISSN: 1740-4398</identifier><identifier>EISSN: 1740-4398</identifier><identifier>DOI: 10.7573/dic.212528</identifier><identifier>PMID: 29899754</identifier><language>eng</language><publisher>England: BioExcel Publishing Ltd</publisher><subject>immunocheckpoint inhibitors ; immunotherapy ; PD-1 ; renal cell carcinoma ; tyrosine kinase inhibitors</subject><ispartof>Drugs in Context, 2018, Vol.7, p.212528-8</ispartof><rights>Copyright © 2018 Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, Battelli N, Lopez-Beltran A. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3598-8d7a4b68df2e39eb42de1f960b7c058c5ce8f0018b1c48b71669a35ec61b28403</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992965/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992965/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29899754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><creatorcontrib>Di Nunno, Vincenzo</creatorcontrib><creatorcontrib>Conti, Alessandro</creatorcontrib><creatorcontrib>Cimadamore, Alessia</creatorcontrib><creatorcontrib>Scarpelli, Marina</creatorcontrib><creatorcontrib>Montironi, Rodolfo</creatorcontrib><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Battelli, Nicola</creatorcontrib><creatorcontrib>Lopez-Beltran, Antonio</creatorcontrib><title>Immunotherapy in renal cell carcinoma: latest evidence and clinical implications</title><title>Drugs in Context</title><addtitle>Drugs Context</addtitle><description>Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.</description><subject>immunocheckpoint inhibitors</subject><subject>immunotherapy</subject><subject>PD-1</subject><subject>renal cell carcinoma</subject><subject>tyrosine kinase inhibitors</subject><issn>1745-1981</issn><issn>1740-4398</issn><issn>1740-4398</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkV1LHTEQhkNpqR_tjT-g7GUR1ibZfHohiLT2gNBe6HWYTWY1spucJnsE_717PCr1ZmaYeXlmmJeQI0ZPtNTdjxD9CWdccvOB7DMtaCs6az4-17Jl1rA9clDrPaVCUqU-kz1ujbVain3ydzVNm5TnOyywfmxiagomGBuP4xKg-JjyBKfNCDPWucGHGDB5bCCFxo8xRb-I47Qel2KOOdUv5NMAY8WvL_mQ3Pz6eX3xu736c7m6OL9qfSetaU3QIHplwsCxs9gLHpANVtFeeyqNlx7NQCkzPfPC9JopZaGT6BXruRG0OySrHTdkuHfrEicojy5DdM-NXG4dlDn6EZ02XgmGVAycip4pMJZb7Y1kQkgIcmGd7VjrTT9h8JjmAuM76PtJinfuNj84aReS2gK-vwBK_rdZHuWmWLcvhIR5Ux2nUiqmFdvefbyT-pJrLTi8rWHUbe10i51uZ-ci_vb_YW_SV_-6J3OWm4E</recordid><startdate>2018</startdate><enddate>2018</enddate><creator>Santoni, Matteo</creator><creator>Massari, Francesco</creator><creator>Di Nunno, Vincenzo</creator><creator>Conti, Alessandro</creator><creator>Cimadamore, Alessia</creator><creator>Scarpelli, Marina</creator><creator>Montironi, Rodolfo</creator><creator>Cheng, Liang</creator><creator>Battelli, Nicola</creator><creator>Lopez-Beltran, Antonio</creator><general>BioExcel Publishing Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2018</creationdate><title>Immunotherapy in renal cell carcinoma: latest evidence and clinical implications</title><author>Santoni, Matteo ; Massari, Francesco ; Di Nunno, Vincenzo ; Conti, Alessandro ; Cimadamore, Alessia ; Scarpelli, Marina ; Montironi, Rodolfo ; Cheng, Liang ; Battelli, Nicola ; Lopez-Beltran, Antonio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3598-8d7a4b68df2e39eb42de1f960b7c058c5ce8f0018b1c48b71669a35ec61b28403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>immunocheckpoint inhibitors</topic><topic>immunotherapy</topic><topic>PD-1</topic><topic>renal cell carcinoma</topic><topic>tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santoni, Matteo</creatorcontrib><creatorcontrib>Massari, Francesco</creatorcontrib><creatorcontrib>Di Nunno, Vincenzo</creatorcontrib><creatorcontrib>Conti, Alessandro</creatorcontrib><creatorcontrib>Cimadamore, Alessia</creatorcontrib><creatorcontrib>Scarpelli, Marina</creatorcontrib><creatorcontrib>Montironi, Rodolfo</creatorcontrib><creatorcontrib>Cheng, Liang</creatorcontrib><creatorcontrib>Battelli, Nicola</creatorcontrib><creatorcontrib>Lopez-Beltran, Antonio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Drugs in Context</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santoni, Matteo</au><au>Massari, Francesco</au><au>Di Nunno, Vincenzo</au><au>Conti, Alessandro</au><au>Cimadamore, Alessia</au><au>Scarpelli, Marina</au><au>Montironi, Rodolfo</au><au>Cheng, Liang</au><au>Battelli, Nicola</au><au>Lopez-Beltran, Antonio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy in renal cell carcinoma: latest evidence and clinical implications</atitle><jtitle>Drugs in Context</jtitle><addtitle>Drugs Context</addtitle><date>2018</date><risdate>2018</risdate><volume>7</volume><spage>212528</spage><epage>8</epage><pages>212528-8</pages><issn>1745-1981</issn><issn>1740-4398</issn><eissn>1740-4398</eissn><abstract>Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC). The optimal combination between immunotherapy and targeted agents (as well as the possible favourable sequential therapy of these two classes of drugs) remains an open question at this moment. Several trials are currently underway to assess the combination of anti-programmed-death 1 (PD-1) or anti-PD-ligand(L)1 agents with other immunotherapies or with anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). In this editorial, we described the results of the most recent clinical trials on the use of immunotherapies in RCC and the emerging data on the research for reliable biomarkers of tumour response in this setting. In addition, we have focused on the role of the gut microbiome and tumour microenvironment in the development of future therapeutic strategies for RCC patients.</abstract><cop>England</cop><pub>BioExcel Publishing Ltd</pub><pmid>29899754</pmid><doi>10.7573/dic.212528</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1745-1981 |
| ispartof | Drugs in Context, 2018, Vol.7, p.212528-8 |
| issn | 1745-1981 1740-4398 1740-4398 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5992965 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | immunocheckpoint inhibitors immunotherapy PD-1 renal cell carcinoma tyrosine kinase inhibitors |
| title | Immunotherapy in renal cell carcinoma: latest evidence and clinical implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A06%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20in%20renal%20cell%20carcinoma:%20latest%20evidence%20and%20clinical%20implications&rft.jtitle=Drugs%20in%20Context&rft.au=Santoni,%20Matteo&rft.date=2018&rft.volume=7&rft.spage=212528&rft.epage=8&rft.pages=212528-8&rft.issn=1745-1981&rft.eissn=1740-4398&rft_id=info:doi/10.7573/dic.212528&rft_dat=%3Cproquest_doaj_%3E2055617610%3C/proquest_doaj_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2055617610&rft_id=info:pmid/29899754&rft_doaj_id=oai_doaj_org_article_78c641e04f204b16a89297c851445ad5&rfr_iscdi=true |